Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 22,875,679	$ 26,043,897
Contracts and grants receivable	123,692	138,889
Research and development incentives receivable	121,238	103,832
Prepaid expenses and other current assets	353,635	282,903
Total current assets	23,474,244	26,569,521
Security deposit	22,777	22,777
Office furniture and equipment, net of accumulated depreciation of $172,204 and $167,848	27,686	22,220
Deferred issuance cost	20,266	20,266
Right-of-use lease assets	75,230	106,155
Research and development incentive receivable	50,566	121,238
Other assets	3,875	7,750
Total assets	23,674,644	26,869,927
Current liabilities:
Accounts payable	4,518,174	2,925,544
Accrued expenses	2,592,296	2,956,545
Accrued compensation	38,050	302,936
Lease liabilities - current	75,230	106,151
Total current liabilities	7,223,750	6,291,176
Non-current liabilities:
Convertible debt, net of debt discount of $133,605 and $143,847	9,866,395	9,856,153
Total liabilities	17,090,145	16,147,329
Commitments and Contingencies
Shareholders' equity:
Preferred stock, 350,000 shares authorized; none issued or outstanding
Common stock, $.001 par value; 75,000,000 shares authorized; 42,954,091 shares and 42,873,445 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	42,954	42,873
Additional paid-in capital	216,531,081	216,402,890
Accumulated other comprehensive income	124,592	41,942
Accumulated deficit	(210,114,128)	(205,765,107)
Total shareholders' equity	6,584,499	10,722,598
Total liabilities and shareholders' equity	$ 23,674,644	$ 26,869,927